User login
Key clinical point: Users of hormone-containing intrauterine (HIUD) devices had no significant increase in risk of developing precancerous cervical lesions than women who used other contraceptives.
Major finding: Women who used hormone-containing IUDs had the same risk as users of copper IUDs (CIUD) of developing cervical intraepithelial neoplasia 3+ (CIN3+) with adjusted relative risk of 1.08 over 5 years. The risk of CIN3+ was lower for the HIUD group and CIUD group compared to users of oral contraceptives (aRR 0.63 and aRR 0.58, respectively).
Study details: The data come from a population-based cohort study of women aged 26-50 years in Denmark, using registry data from 2008 to 2011; the study population included 60,551 users of HIUDs, 30,303 users of CIUDs, and 165,627 users of oral contraceptives.
Disclosures: The study was supported by the A.P. Møller Foundation for the Advancement of Medical Science, the Else and Mogens Wedell-Wedellborgs Fund, the Direktør Emil C. Hertz og Hustru Inger Hertz Fund, and the Fund for Development of Evidence Based Medicine in Private Specialized Practices. Lead author Dr. Skortengaard had no financial conflicts to disclose.
Source: Skortengaard M et al. Hum Reprod. 2021 Jun 18. doi: 10.1093/humrep/deab066.
Key clinical point: Users of hormone-containing intrauterine (HIUD) devices had no significant increase in risk of developing precancerous cervical lesions than women who used other contraceptives.
Major finding: Women who used hormone-containing IUDs had the same risk as users of copper IUDs (CIUD) of developing cervical intraepithelial neoplasia 3+ (CIN3+) with adjusted relative risk of 1.08 over 5 years. The risk of CIN3+ was lower for the HIUD group and CIUD group compared to users of oral contraceptives (aRR 0.63 and aRR 0.58, respectively).
Study details: The data come from a population-based cohort study of women aged 26-50 years in Denmark, using registry data from 2008 to 2011; the study population included 60,551 users of HIUDs, 30,303 users of CIUDs, and 165,627 users of oral contraceptives.
Disclosures: The study was supported by the A.P. Møller Foundation for the Advancement of Medical Science, the Else and Mogens Wedell-Wedellborgs Fund, the Direktør Emil C. Hertz og Hustru Inger Hertz Fund, and the Fund for Development of Evidence Based Medicine in Private Specialized Practices. Lead author Dr. Skortengaard had no financial conflicts to disclose.
Source: Skortengaard M et al. Hum Reprod. 2021 Jun 18. doi: 10.1093/humrep/deab066.
Key clinical point: Users of hormone-containing intrauterine (HIUD) devices had no significant increase in risk of developing precancerous cervical lesions than women who used other contraceptives.
Major finding: Women who used hormone-containing IUDs had the same risk as users of copper IUDs (CIUD) of developing cervical intraepithelial neoplasia 3+ (CIN3+) with adjusted relative risk of 1.08 over 5 years. The risk of CIN3+ was lower for the HIUD group and CIUD group compared to users of oral contraceptives (aRR 0.63 and aRR 0.58, respectively).
Study details: The data come from a population-based cohort study of women aged 26-50 years in Denmark, using registry data from 2008 to 2011; the study population included 60,551 users of HIUDs, 30,303 users of CIUDs, and 165,627 users of oral contraceptives.
Disclosures: The study was supported by the A.P. Møller Foundation for the Advancement of Medical Science, the Else and Mogens Wedell-Wedellborgs Fund, the Direktør Emil C. Hertz og Hustru Inger Hertz Fund, and the Fund for Development of Evidence Based Medicine in Private Specialized Practices. Lead author Dr. Skortengaard had no financial conflicts to disclose.
Source: Skortengaard M et al. Hum Reprod. 2021 Jun 18. doi: 10.1093/humrep/deab066.